Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

99mtc-labeled RGD (arginine-glycine-aspartic acid) polypeptide tumor diagnosis medicament and preparation method thereof

A 99mtc, 99mtc-hynic-k technology, applied in the direction of radioactive carriers, can solve the problem of accelerating the metabolism of imaging agents

Inactive Publication Date: 2012-07-11
安徽筑梦生物科技有限公司
View PDF3 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the existing RGD polypeptide dimer imaging agents still have certain deficiencies in the metabolism of non-target organs. It is necessary to invent new RGD polypeptide dimer imaging agents to further accelerate imaging by changing the structure of the ligand. The metabolic rate of the drug in non-target organs such as lung, liver and kidney, thereby reducing the radioactive background and improving the image quality of tumor imaging

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • 99mtc-labeled RGD (arginine-glycine-aspartic acid) polypeptide tumor diagnosis medicament and preparation method thereof
  • 99mtc-labeled RGD (arginine-glycine-aspartic acid) polypeptide tumor diagnosis medicament and preparation method thereof
  • 99mtc-labeled RGD (arginine-glycine-aspartic acid) polypeptide tumor diagnosis medicament and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0018] One. The preparation method of RGD polypeptide radiopharmaceutical

[0019] 1. Materials and Equipment

[0020] The required chemicals were purchased from Sigma / Aldrich, USA and used without further purification. Boc-Lys(nicotinoyl)-OH and Lys(Boc) 2 -OSu was purchased from Bachem Biosciences, USA. RGD cyclic peptide, E[c(RGDfK)] 2 (RGD 2 ), G 3 -E[G 3 -c(RGDfK)] 2 (3G-RGD 2 ) and PEG 4 -E[PEG 4 -c(RGDfK)] 2 (3P-RGD 2 ) was manufactured by Peptides International Company (Louisville, KY) of the United States according to conventional processes.

[0021] The NMR (nuclear magnetic resonance) spectrum data is recorded by a 300MHz Bruzker ARX FT nuclear magnetic resonance spectrometer, and the displayed spectrum data is the chemical shift value (ppm) referenced to TMS (trimethylsilyl). ESI (electrospray ionization) mass spectrometry data were collected on a Finnigan LCQ conventional mass spectrometer. 99m TCO 4 - Purchased from Atom Hi-Tech Co., Ltd.

[0022...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to three RGD (Arginine-Glycine-Aspartic acid) polypeptide radioactive medicaments for positive tumor diagnosis of an intergrinalphavbeta3 receptor and preparation methods thereof. The three RGD polypeptide radioactive medicaments are structurally RGD annular dipolymers, and radioactive nuclein 99mTc labeling is performed through a dual-functional chelating agent. The medicaments are mainly characterized in that: a [K(NIC)] structure which is connected with RGD is used for replacing the conventional 99mTc-labeled synergistic ligand, i.e., trisodium salt of tri(m-sulfonphenyl) phosphine (TPPTS), so that the molecular weight of a medicament structure is reduced, and the metabolism velocity of a radioactive medicament in a non-target organ is increased. The three radioactive medicaments include 99mTc-HYNIC-K(NIC)-RGD2, 99mTc-HYNIC-K(NIC)-3G-RGD2 and 99mTc-HYNIC-K(NIC)-3P-RGD2, and are colorless and transparent liquid injections.

Description

technical field [0001] The present invention relates to radiopharmaceuticals for tumor diagnosis, in particular to intergrin alpha v beta 3 Three RGD polypeptide radiopharmaceuticals for the diagnosis of receptor-positive tumors and their preparation methods. Background technique [0002] According to the statistics of the World Health Organization (WHO), more than 11 million people suffer from malignant tumors every year in the world, and more than 8 million people die from the disease. The incidence of malignant tumors is also showing a clear upward trend in my country. According to national health statistics, in the past two years, malignant tumors have accounted for the first cause of death among urban residents in my country, and there are about 2.2 million new patients every year. [0003] In recent years, the treatment methods for malignant tumors have been continuously developed. Not only traditional chemotherapy and radiotherapy techniques have become more standar...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K51/08A61K103/10
Inventor 高伟
Owner 安徽筑梦生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com